Bruce D. Cheson

13.4k total citations · 4 hit papers
130 papers, 9.6k citations indexed

About

Bruce D. Cheson is a scholar working on Pathology and Forensic Medicine, Genetics and Oncology. According to data from OpenAlex, Bruce D. Cheson has authored 130 papers receiving a total of 9.6k indexed citations (citations by other indexed papers that have themselves been cited), including 66 papers in Pathology and Forensic Medicine, 58 papers in Genetics and 36 papers in Oncology. Recurrent topics in Bruce D. Cheson's work include Lymphoma Diagnosis and Treatment (66 papers), Chronic Lymphocytic Leukemia Research (57 papers) and Multiple Myeloma Research and Treatments (11 papers). Bruce D. Cheson is often cited by papers focused on Lymphoma Diagnosis and Treatment (66 papers), Chronic Lymphocytic Leukemia Research (57 papers) and Multiple Myeloma Research and Treatments (11 papers). Bruce D. Cheson collaborates with scholars based in United States, Italy and Germany. Bruce D. Cheson's co-authors include Nancy L. Harris, Julie M. Vose, George P. Canellos, Fernando Cabanillas, Richard I. Fisher, Tim Lister, Sandra J. Horning, Margaret A. Shipp, Antonio J Grillo-López and Joseph M. Connors and has published in prestigious journals such as New England Journal of Medicine, JAMA and Journal of Clinical Oncology.

In The Last Decade

Bruce D. Cheson

122 papers receiving 9.4k citations

Hit Papers

Report of an Internationa... 1990 2026 2002 2014 1999 2007 2000 1990 500 1000 1.5k 2.0k 2.5k

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Bruce D. Cheson United States 37 5.3k 3.7k 3.0k 2.9k 1.9k 130 9.6k
Morton Coleman United States 47 4.8k 0.9× 3.0k 0.8× 3.3k 1.1× 2.1k 0.7× 1.6k 0.9× 306 8.2k
Myron S. Czuczman United States 50 6.5k 1.2× 4.6k 1.2× 3.5k 1.2× 1.3k 0.5× 2.0k 1.1× 241 10.4k
Luca Baldini Italy 48 3.7k 0.7× 2.5k 0.7× 2.8k 0.9× 1.9k 0.7× 2.3k 1.2× 261 7.8k
Michael Crump Canada 49 5.6k 1.0× 5.3k 1.4× 2.4k 0.8× 1.0k 0.4× 1.6k 0.9× 310 9.8k
Brad S. Kahl United States 49 7.8k 1.5× 5.6k 1.5× 5.1k 1.7× 1.5k 0.5× 2.4k 1.3× 385 11.3k
Jorge Romaguera United States 52 7.1k 1.3× 5.4k 1.4× 3.3k 1.1× 950 0.3× 1.6k 0.8× 281 9.8k
Eric L. Sievers United States 38 3.3k 0.6× 5.1k 1.4× 1.3k 0.4× 2.6k 0.9× 2.9k 1.5× 101 10.3k
Francesc Bosch Spain 48 5.6k 1.0× 3.4k 0.9× 4.3k 1.4× 1.2k 0.4× 2.0k 1.0× 243 8.7k
Fredrick B. Hagemeister United States 52 6.1k 1.2× 4.3k 1.2× 2.7k 0.9× 925 0.3× 791 0.4× 257 8.5k
Steven Le Gouill France 47 3.7k 0.7× 3.3k 0.9× 1.7k 0.6× 1.7k 0.6× 2.1k 1.1× 312 7.2k

Countries citing papers authored by Bruce D. Cheson

Since Specialization
Citations

This map shows the geographic impact of Bruce D. Cheson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bruce D. Cheson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bruce D. Cheson more than expected).

Fields of papers citing papers by Bruce D. Cheson

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bruce D. Cheson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bruce D. Cheson. The network helps show where Bruce D. Cheson may publish in the future.

Co-authorship network of co-authors of Bruce D. Cheson

This figure shows the co-authorship network connecting the top 25 collaborators of Bruce D. Cheson. A scholar is included among the top collaborators of Bruce D. Cheson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bruce D. Cheson. Bruce D. Cheson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Cheson, Bruce D., Michael J. Keating, & William Plunkett. (2021). Nucleoside Analogs in Cancer Therapy. 2 indexed citations
2.
Ujjani, Chaitra S., Anthony R. Mato, Brian T. Hill, et al.. (2020). <p>The Impact of Age on Survival in CLL Patients Receiving Ibrutinib as Initial Therapy</p>. SHILAP Revista de lepidopterología. Volume 10. 1–5. 6 indexed citations
3.
Press, Oliver W., Joseph M. Unger, Lisa M. Rimsza, et al.. (2013). A Comparative Analysis of Prognostic Factor Models for Follicular Lymphoma Based on a Phase III Trial of CHOP–Rituximab versus CHOP + 131Iodine—Tositumomab. Clinical Cancer Research. 19(23). 6624–6632. 32 indexed citations
4.
Wilson, Wyndham H., Sin‐Ho Jung, Pierluigi Porcu, et al.. (2011). A Cancer and Leukemia Group B multi-center study of DA-EPOCH-rituximab in untreated diffuse large B-cell lymphoma with analysis of outcome by molecular subtype. Haematologica. 97(5). 758–765. 125 indexed citations
5.
Goswami, Trishna, et al.. (2010). The Sarcoid-Lymphoma Syndrome. Clinical Lymphoma Myeloma & Leukemia. 10(4). 241–247. 24 indexed citations
6.
Kahl, Brad S., Bruce D. Cheson, & Jonathan W. Friedberg. (2010). Clinical Roundtable Monograph: current treatment options for NHL patients refractory to standard therapy: recent data in single-agent and combination therapy.. PubMed. 8(5). 1–16. 6 indexed citations
7.
Juweid, Malik E., Sigrid Stroobants, Otto S. Hoekstra, et al.. (2007). Use of Positron Emission Tomography for Response Assessment of Lymphoma: Consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. Journal of Clinical Oncology. 25(5). 571–578. 967 indexed citations breakdown →
8.
Wilson, Wyndham H., Pierluigi Porcu, David D. Hurd, et al.. (2005). Phase II study of dose-adjusted EPOCH-R in untreated de novo CD20+ diffuse large B-cell lymphoma (DLBCL)-CALGB 50103. Journal of Clinical Oncology. 23(16_suppl). 6530–6530. 4 indexed citations
10.
Kantarjian, Hagop M., Moshe Talpaz, Valeria Santini, et al.. (2001). Homoharringtonine. Cancer. 92(6). 1591–1605. 144 indexed citations
11.
Cheson, Bruce D., et al.. (2000). Management of Chronic Lymphocytic Leukaemia. Drugs & Aging. 16(1). 9–27. 32 indexed citations
12.
Kanti, R., Bercedis L. Peterson, Frederick R. Appelbaum, et al.. (2000). Fludarabine Compared with Chlorambucil as Primary Therapy for Chronic Lymphocytic Leukemia. New England Journal of Medicine. 343(24). 1750–1757. 754 indexed citations breakdown →
13.
Cheson, Bruce D., Sandra J. Horning, B Coiffier, et al.. (1999). Report of an International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas. Journal of Clinical Oncology. 17(4). 1244–1244. 2816 indexed citations breakdown →
14.
Cheson, Bruce D.. (1998). Current approaches to therapy for indolent non-Hodgkin's lymphoma.. PubMed. 12(10 Suppl 8). 25–34. 5 indexed citations
15.
Barlogie, Bart, Sundar Jagannath, David H. Vesole, et al.. (1997). Superiority of Tandem Autologous Transplantation Over Standard Therapy for Previously Untreated Multiple Myeloma. Blood. 89(3). 789–793. 415 indexed citations
16.
Vesole, DH, Guido Tricot, S Jagannath, et al.. (1996). Autotransplants in multiple myeloma: what have we learned?. Blood. 88(3). 838–847. 117 indexed citations
17.
Cheson, Bruce D.. (1991). New modalities of therapy in chronic lymphocytic leukemia. Critical Reviews in Oncology/Hematology. 11(3). 167–177. 4 indexed citations
18.
Cheson, Bruce D., et al.. (1990). Clinical trials referral resource.. PubMed. 11(11). 1144, 1147–116, 118. 77 indexed citations
19.
Grem, Jean L., Susan A. King, Bruce D. Cheson, B Leyland-Jones, & R. Wittes. (1989). Pentostatin in Hairy Cell Leukemia: Treatment by the Special Exception Mechanism. JNCI Journal of the National Cancer Institute. 81(6). 448–453. 28 indexed citations
20.
Cheson, Bruce D., et al.. (1977). The oxidative killing mechanisms of the neutrophil.. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 3. 1–65. 54 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026